Medicus Pharma Regains Nasdaq Minimum Bid Compliance
Nasdaq confirmed Medicus Pharma has met the $1 minimum closing bid price requirement for 10 consecutive business days.
Updated on Nov. 1, 2026 in Public Companies
Nasdaq's Listing Qualifications Department sent Medicus Pharma written confirmation that the company has regained compliance with the exchange's minimum share price requirement. The determination followed a qualifying period from October 12 through October 23, during which the company's common shares maintained a closing bid price of at least $1.
Why it matters
Regaining compliance resolves the deficiency under Nasdaq Listing Rule 5550(a)(2), allowing Medicus Pharma to continue trading on the Nasdaq Capital Market under its existing listing status. The company remains subject to Nasdaq's other continued listing requirements, and future compliance with the minimum bid price standard is not guaranteed.
Medicus Pharma's common shares held a closing bid price of at least $1 for 10 consecutive business days, from October 12 through October 23. The source does not disclose the exact share price during that window or the company's broader financial metrics.
The players
Nasdaq
The Nasdaq Stock Market is a U.S. securities exchange that operates the Nasdaq Capital Market and sets the minimum bid price and other continued listing standards that companies must meet to remain listed.
Medicus Pharma Ltd.
Medicus Pharma is a company that develops investigational therapeutics and trades on the Nasdaq Capital Market.
The details
Medicus Pharma, a developer of investigational therapeutics, received written confirmation from Nasdaq's Listing Qualifications Department after meeting the exchange's minimum closing bid price threshold. Additional information was provided in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.
Timeline
October 12, 2026 through October 23, 2026: Qualifying period of 10 consecutive business days of compliance.
October 23, 2026: Nasdaq sent written confirmation of compliance.
Market Landscape
Under Nasdaq Listing Rule 5550(a)(2), companies whose shares trade below $1 face a deficiency notice and must regain a closing bid price of at least $1 for 10 consecutive business days to be restored to compliance. Medicus Pharma's confirmation follows that exact cure mechanism, which applies across all companies listed on the Nasdaq Capital Market.
For investors holding Medicus Pharma shares, the restored compliance removes the immediate risk of delisting tied to the minimum bid price deficiency. Holders should still monitor the stock, since the company must keep meeting Nasdaq's other continued listing requirements and future compliance is not guaranteed.
The takeaway
A regained listing status reduces near-term delisting risk, but it does not guarantee that a company's share price will stay above the exchange's minimum for the long term. Investors should watch whether Medicus Pharma sustains its price level beyond this compliance window.
Further reading
Explore more coverage of Public Companies to see how other listed firms handle exchange listing requirements.
